Neuspera Sacral Neuromodulation System
Neuspera Medical, Inc. · Decision date Aug 15, 2025
What did the FDA approve?
FDA records P240031/S001 as a supplement to PMA P240031, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Aug 15, 2025.
FDA approval order statement
approval of the protocol for the post-approval study (PAS) of Neuspera Sacral Neuromodulation System.
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track No User Fee
- Clinical specialty
- Gastroenterology, Urology
- Decision date
- Aug 15, 2025
- FDA change category
- Postapproval Study Protocol
Regulatory record facts
- Identifier
- P240031/S001
- Regulatory pathway
- PMA supplement
- Applicant
- Neuspera Medical, Inc.
- Product code
- EZW
- Decision code
- APPR
- Decision date
- Aug 15, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Stimulator, electrical, implantable, for incontinence.
- Applicant
- Neuspera Medical, Inc.
- Product code
- EZW
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P240031/S001 received
Application receipt date recorded by FDA.
P240031/S001 · FDA decision
Normal 180 Day Track No User Fee
P240031/S004 · Related supplement
Neuspera Sacral Neuromodulation (SNM) System
P240031/S003 · Related supplement
Neuspera Sacral Neuromodulation (SNM) System
P240031/S005 · Related supplement
Neuspera Sacral Neuromodulation (SNM) System
Timeline entries are records held by MedtechLedger for P240031. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P240031
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Neuspera Sacral Neuromodulation (SNM) SystemP240031/S004 | Neuspera Medical, Inc. | PMA supplement | Apr 3, 2026 | FDA |
Neuspera Sacral Neuromodulation (SNM) SystemP240031/S003 | Neuspera Medical, Inc. | PMA supplement | Apr 21, 2026 | FDA |
Neuspera Sacral Neuromodulation (SNM) SystemP240031/S005 | Neuspera Medical, Inc. | PMA supplement | Aug 21, 2026 | FDA |
Explore the linked device profile
Other records with product code EZW
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic Neuromodulation | PMA supplement | Oct 29, 2026 | FDA | |
| Medtronic Neuromodulation | PMA supplement | Oct 9, 2026 | FDA | |
| Medtronic Neuromodulation | PMA supplement | Oct 6, 2026 | FDA | |
| Medtronic Neuromodulation | PMA supplement | Sep 14, 2026 | FDA | |
| Medtronic Neuromodulation | PMA supplement | Aug 14, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Neuspera Medical, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 51 Daggett Dr., San Jose, CA, 95134
Sources and methodology
- Original FDA record: P240031/S001
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



